Bayer receives first approval for Lynkuet in UK as treatment for vasomotor symptoms associated with menopause
The UK authorization is based on positive results from the Phase III OASIS-1, -2, and -3 trials
The UK authorization is based on positive results from the Phase III OASIS-1, -2, and -3 trials
Subscribe To Our Newsletter & Stay Updated